Press Releases
Samsung Biologics receives the ‘Honor Award’ in the pharmaceutical sector from CDP Korea Awards
Today on January 26th (Wed), Samsung Biologics received the ‘Honor Award’ in the pharmaceutical sector from CDP Korea Awards as part of CDP (Carbon Disclosure Project), a non profit organization that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts.
CDP runs the global environmental disclosure system and each year organizations measure, manage, and disclose their risks and opportunities on climate change, water security and deforestation in response to climate change and other environmental issues.
First year involved in the disclosure, Samsung Biologics obtained the “Management” level which is the highest grade received in the pharmaceutical sector in Korea. The company received the CDP Korea Award as the first and only biopharmaceutical company, recognized for its continued efforts for decarbonization and eco-friendly management system.
As a leading CDMO, Samsung Biologics is proactively participating in the global movement against climate change and has been engaging in a number of initiatives, including Frontier 1.5D, a collaborative project to develop a climate risk management model with various organizations, and Sustainable Markets Initiative, convened by His Royal Highness The Prince of Wales to decarbonize and lower emissions across industries.
The company also obtained two global ISO certifications for Environmental Management and Energy management in order to further fulfill its social responsibilities and successfully engage in initiatives related to ESG matters.
Today on January 26th (Wed), Samsung Biologics received the ‘Honor Award’ in the pharmaceutical sector from CDP Korea Awards as part of CDP (Carbon Disclosure Project), a non profit organization that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts.
CDP runs the global environmental disclosure system and each year organizations measure, manage, and disclose their risks and opportunities on climate change, water security and deforestation in response to climate change and other environmental issues.
First year involved in the disclosure, Samsung Biologics obtained the “Management” level which is the highest grade received in the pharmaceutical sector in Korea. The company received the CDP Korea Award as the first and only biopharmaceutical company, recognized for its continued efforts for decarbonization and eco-friendly management system.
As a leading CDMO, Samsung Biologics is proactively participating in the global movement against climate change and has been engaging in a number of initiatives, including Frontier 1.5D, a collaborative project to develop a climate risk management model with various organizations, and Sustainable Markets Initiative, convened by His Royal Highness The Prince of Wales to decarbonize and lower emissions across industries.
The company also obtained two global ISO certifications for Environmental Management and Energy management in order to further fulfill its social responsibilities and successfully engage in initiatives related to ESG matters.